Clinscience and OncoBay Clinical Partner to Expand Immuno-Oncology Research Globally

OncoBay Clinical, one of Moffitt Cancer Center’s for-profit subsidiaries, has partnered with Clinscience, a global clinical research organization based in Warsaw, Poland. The investment gives NEUCA Group, Clinscience’s parent company, a majority equity stake in OncoBay. Both companies will work together to advance immuno-oncology research for a global portfolio of clients.

Moffitt created OncoBay Clinical in 2019 as a boutique clinical research organization that offers streamlined, custom-curated services for biopharma and biotech companies conducting research in the immuno-oncology space. During this time, OncoBay has grown to providing services to more than 60 customers, with many trials conducted in tandem with Clinscience. This new partnership builds upon a two-year relationship with Clinscience.

“Moffitt made an investment three years ago when it launched OncoBay, and in that short period of time we have taken this concept to a global entity with an international research footprint,” said James Mulé, IPhD, associate center director of Translational Science at Moffitt and OncoBay advisor. “This new partnership with Clinscience will allow us to continue to provide tailored immuno-oncology on a much larger scale.”

“This innovation collaboration gives us an exciting opportunity to build upon our clinical expertise, innovative analytics and data assessment tools to impact immuno-oncology research globally. The goal is to transform and accelerate discoveries to reach patients more quickly,” said Krystyna Kowalczyk, OncoBay CEO and co-founder.

Kowalczyk will remain CEO of the combined OncoBay and Clinscience operation. She and
Dannelle Palmer, OncoBay’s chief operating officer, will also join NEUCA Group’s leadership team.

Pillsbury Winthrop Shaw Pittman LLP served as legal adviser to NEUCA Group and Clinscience in the transaction. Ropes & Gray LLP served as legal adviser to OncoBay and Moffitt.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”